Trevi Therapeutics Inc (TRVI)

02:12 AM

Trevi Therapeutics (NASDAQ:TRVI) Trading Up 7.2%Here's What Happened - MarketBeat

02:12 AM

Apr 05, 2026

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 earnings call transcript - MSN

Apr 05, 2026

Apr 05, 2026

A Look At Trevi Therapeutics (TRVI) Valuation After FDA End Of Phase 2 Milestone For IPF Chronic Cough - Yahoo Finance

Apr 05, 2026

Apr 04, 2026

TRVI Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 02, 2026

Trevi Therapeutics, Inc. (TRVI) stock price, news, quote and history - Yahoo Finance Australia

Apr 02, 2026

Apr 02, 2026

Trevi Therapeutics, Inc. (TRVI) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 02, 2026

Apr 02, 2026

Trevi Therapeutics to Participate in Upcoming Events - Sahm

Apr 02, 2026

Apr 01, 2026

Trevi brings chronic cough specialists to New York investor day - Stock Titan

Apr 01, 2026

Mar 31, 2026

These analysts revise their forecasts on Trevi Therapeutics following Q4 earnings - MSN

Mar 31, 2026

Mar 28, 2026

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Mar 28, 2026

Mar 28, 2026

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Mar 28, 2026

Mar 27, 2026

Vanguard (TRVI) amends 13G/A after Jan 12, 2026 realignment - Stock Titan

Mar 27, 2026

Mar 25, 2026

Trevi Therapeutics (NASDAQ:TRVI) Shares Up 9.4%What's Next? - MarketBeat

Mar 25, 2026

Mar 22, 2026

Aug Wrap: Will Trevi Therapeutics Inc outperform tech stocks2026 Trading Recap & AI Powered Trade Plan Recommendations - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

TRVI SEC FilingsTrevi Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 21, 2026

Mar 21, 2026

TRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Mar 21, 2026

Mar 21, 2026

Trevi Therapeutics edges higher amid takeover speculation - MSN

Mar 21, 2026

Mar 20, 2026

Research Analysts Issue Forecasts for TRVI FY2026 Earnings - MarketBeat

Mar 20, 2026

Mar 20, 2026

Trevi Therapeutics to Participate in Upcoming September Events - GuruFocus

Mar 20, 2026

Mar 19, 2026

Trading Action: Can Trevi Therapeutics Inc continue delivering strong returnsMarket Risk Summary & Detailed Earnings Play Alerts - baoquankhu1.vn

Mar 19, 2026

Mar 19, 2026

These Analysts Revise Their Forecasts On Trevi Therapeutics Following Q4 Earnings - Sahm

Mar 19, 2026

Mar 19, 2026

TRVI: Jones Trading Lowers Price Target While Maintaining Buy Ra - GuruFocus

Mar 19, 2026

Mar 19, 2026

Trevi Therapeutics (NASDAQ:TRVI) Given New $24.00 Price Target at JonesTrading - MarketBeat

Mar 19, 2026

Mar 19, 2026

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 19, 2026

Mar 19, 2026

Cantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail

Mar 19, 2026

Mar 19, 2026

What is HC Wainwright's Forecast for TRVI Q1 Earnings? - MarketBeat

Mar 19, 2026

Mar 18, 2026

Does Trevi Therapeutics (TRVI) have the potential to rally 102.07% as Wall Street analysts expect? - MSN

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics Q4 Earnings Call Highlights - MarketBeat

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics (TRVI) Q4 Loss Narrows to $0.06/Share vs $0.10 Estimate, 37% Better Than Expected - news.alphastreet.com

Mar 18, 2026

Mar 18, 2026

Morgan Stanley Lowers Price Target for Trevi Therapeutics (TRVI) to $18.00 | TRVI Stock News - gurufocus.com

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics (NASDAQ:TRVI) Given New $18.00 Price Target at Morgan Stanley - MarketBeat

Mar 18, 2026

Mar 18, 2026

Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating By Investing.com - Investing.com India

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics Chronic Cough Programs: FDA End-of-Phase 2 Meeting & Phase III PlansNews and Statistics - IndexBox

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics 2025 Annual Report Highlights: Haduvio Development, Clinical Progress, and Competitive Position - Minichart

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics plans two pivotal phase III trials for IPF-related chronic cough as FDA alignment achieved - MSN

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics (TRVI) Earnings Transcript - AOL.com

Mar 18, 2026

Mar 18, 2026

TRVI: Today's Analyst Rating Maintained at Buy with $19 Target | - gurufocus.com

Mar 18, 2026

Mar 18, 2026

Needham raises Trevi Therapeutics stock price target on trial plans By Investing.com - Investing.com Canada

Mar 18, 2026

Mar 18, 2026

Cantor Fitzgerald reiterates Trevi Therapeutics stock Overweight rating - Investing.com

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics (NASDAQ:TRVI) Earns Buy Rating from D. Boral Capital - MarketBeat

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $24.00 - MarketBeat

Mar 18, 2026

Mar 18, 2026

Trevi Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 18, 2026

Mar 18, 2026

Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga

Mar 18, 2026

Mar 18, 2026

TRVI: Needham Raises Price Target to $24.00 and Maintains Buy Ra - GuruFocus

Mar 18, 2026

Mar 18, 2026

Earnings call transcript: Trevi Therapeutics Q4 2025 earnings beat expectations By Investing.com - Investing.com Australia

Mar 18, 2026